Although, the application of anti-VEGF mAb has been verified and evaluated in a multitude of clinical trials for tumor therapy, because of the multiple effects mediated by blocking VEGF, the efficacy could not be only attributed to MDSC reduction. This evidence concerns the gene VEGFA and neoplasm.